Literature DB >> 8857929

Comparison of the effects of the thrombin inhibitor r-hirudin in four animal models of neointima formation after arterial injury.

C Gerdes1, V Faber-Steinfeld, O Yalkinoglu, S Wohlfeil.   

Abstract

Thrombin has been implicated as a contributing factor to restenosis after vessel reopening procedures. We compared the ability of the direct thrombin inhibitor recombinant (r-) hirudin to reduce neointimal growth in different animal models of arterial injury. Carotid arteries of rats, rabbits, and hypercholesterolemic minipigs were injured by withdrawal of an inflated balloon catheter. In addition, we used a double-lesion model in rabbits, which involved balloon angioplasty of a preexisting lesion induced by carotid denudation 4 weeks earlier. r-Hirudin was given in all four animal models as a short-term application (bolus of 1 mg/kg i.v. immediately before injury, followed by infusion of 1 mg.kg-1.h-1 for 2 hours, and an injection of 6 mg/kg SC). Additionally, we investigated the effects of prolonged treatment (intravenous infusion for 3 and 14 days) in rats. Inhibition of thrombin was monitored by determination of activated partial thromboplastin time, and histomorphometric analysis of the arteries was performed after 2 (rats) or 4 (rabbits and minipigs) weeks. In rabbits, short-term r-hirudin treatment reduced neointimal area by 59% (single-injury model, P = .05) and 44% (double-injury model, P = .02). In rats and minipigs no inhibition of neointimal growth was observed after short-term r-hirudin application. A 3- or 14-day infusion of r-hirudin in rats, however, resulted in 25% (P = .007) and 27% (P = .003) reductions in neointimal area, respectively. In conclusion, there is considerable interspecies variation in the time frame of susceptibility for reduction of neointimal growth by inhibition of thrombin after arterial injury. These results demonstrate the importance of testing potential antirestenotic treatments in an array of different animal models.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8857929     DOI: 10.1161/01.atv.16.10.1306

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  8 in total

1.  Noncanonical Matrix Metalloprotease 1-Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis.

Authors:  Rajashree Rana; Tianfang Huang; Georgios Koukos; Elizabeth K Fletcher; Susan E Turner; Andrew Shearer; Paul A Gurbel; Jeffrey J Rade; Carey D Kimmelstiel; Kevin P Bliden; Lidija Covic; Athan Kuliopulos
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-04-05       Impact factor: 8.311

2.  Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia-reperfusion injury by reducing inflammation.

Authors:  J H Erlich; E M Boyle; J Labriola; J C Kovacich; R A Santucci; C Fearns; E N Morgan; W Yun; T Luther; O Kojikawa; T R Martin; T H Pohlman; E D Verrier; N Mackman
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

3.  Suppression of arterial intimal hyperplasia by cilostamide, a cyclic nucleotide phosphodiesterase 3 inhibitor, in a rat balloon double-injury model.

Authors:  Y Inoue; K Toga; T Sudo; K Tachibana; S Tochizawa; Y Kimura; Y Yoshida; H Hidaka
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

4.  Syndecan-1: an inhibitor of arterial smooth muscle cell growth and intimal hyperplasia.

Authors:  Nozomi Fukai; Richard D Kenagy; Lihua Chen; Lu Gao; Guenter Daum; Alexander W Clowes
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-07-10       Impact factor: 8.311

5.  Proliferative capacity of vein graft smooth muscle cells and fibroblasts in vitro correlates with graft stenosis.

Authors:  Richard D Kenagy; Nozomi Fukai; Seung-Kee Min; Florencia Jalikis; Ted R Kohler; Alexander W Clowes
Journal:  J Vasc Surg       Date:  2009-05       Impact factor: 4.268

6.  Strain-dependent embryonic lethality and exaggerated vascular remodeling in heparin cofactor II-deficient mice.

Authors:  Ken-ichi Aihara; Hiroyuki Azuma; Masashi Akaike; Yasumasa Ikeda; Masataka Sata; Nobuyuki Takamori; Shusuke Yagi; Takashi Iwase; Yuka Sumitomo; Hirotaka Kawano; Takashi Yamada; Toru Fukuda; Takahiro Matsumoto; Keisuke Sekine; Takashi Sato; Yuko Nakamichi; Yoko Yamamoto; Kimihiro Yoshimura; Tomoyuki Watanabe; Takashi Nakamura; Akimasa Oomizu; Minoru Tsukada; Hideki Hayashi; Toshiki Sudo; Shigeaki Kato; Toshio Matsumoto
Journal:  J Clin Invest       Date:  2007-06       Impact factor: 14.808

7.  Evaluation of drug release from paclitaxel + hirudin-eluting balloons and the resulting vascular reactivity in healthy pigs.

Authors:  Xian Wang; Hongmei Li; Xiaoting Sun; Xiaohang Wang; Gangyin Wang
Journal:  Exp Ther Med       Date:  2018-08-23       Impact factor: 2.447

8.  Nonmalignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin-rich thrombus.

Authors:  Ellen G Driever; Fien A von Meijenfeldt; Jelle Adelmeijer; Robbert J de Haas; Marius C van den Heuvel; Chandrasekaran Nagasami; John W Weisel; Constantino Fondevila; Robert J Porte; Anabel Blasi; Nigel Heaton; Stephen Gregory; Pauline Kane; William Bernal; Yoh Zen; Ton Lisman
Journal:  Hepatology       Date:  2021-12-05       Impact factor: 17.298

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.